Merck & Co., Inc: Hepatitis C, Chronic trials
The registry lists 110 Hepatitis C, Chronic studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 81 have results posted.
Phase 1 17Phase 2 23Phase 3 34Phase 4 8No phase 35(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)CompletedNCT00724295
- Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)CompletedNCT00724230
- Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)TerminatedNCT00723879
- An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)WithdrawnNCT00704756
- Study to Evaluate Drug-drug Interaction Between Valopicitabine and RibavirinCompletedNCT00395421Phase 2
- Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)CompletedNCT00237484Phase 3
- Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis CCompletedNCT00227435Phase 1/2
- Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard TherapyCompletedNCT00120861Phase 2
- Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis CCompletedNCT00120835Phase 1/2
- A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis CCompletedNCT00118768Phase 2